Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Befovacimab in Severe Hemophilia
NCT03996486Phase 1Withdrawn
- Sponsor
- Bayer
- Start
- Oct 2019
- Primary completion
- May 2020
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of befovacimab in hemophilia A and hemophilia B (HB), sponsored by Bayer. Primary endpoints: Frequency of drug-related adverse events up to 3 months, Frequency of drug-related serious adverse events up to 3 months and 1 more. Planned start Oct 2019; status: withdrawn.
02
Drugs
befovacimab
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT03996486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03996486.